Clinical Trial Search

Primary: Percentage of Participants Reporting One or More Treatment-Related Ocular Surface Adverse Events — 33.3; 37.7 percentage of participants — p=0.148

Primary: Flash Electroretinogram (FERG) Module Using Diopsys NOVA (Neuro Optic Vision Assessment) Amplitude — -1.68 micro volts

Primary: Number of Seroprotected Subjects Against Diphteria (D) and Tetanus (T) Toxoid Antigens — 677; 614; 93; 79 Participants

Primary: Change From Baseline in Weekly CSBMs Frequency Over the 12-Week Treatment Period (mITT Population) — 1.28; 2.12; 2.74; 2.44 CSBMs per week

Primary: Disability Rating Scale — 12.5; 9.7; 8.5; 6.0 units on a scale — p=0.021

Primary: Number of Subjects With Grade 3 Solicited Local Symptoms — 1; 0; 1; 0 Participants

Primary: 6 Item Hamilton Depression Rating Scale — 7.4; 7.6 units on a scale

Primary: Change From Baseline in Area Under the Curve (AUC) of Pain Intensity and Relief Scores (SPRID) — 2.68; 3.30; 2.62; 1.93 units on a scale*hour — p=<0.0001

Primary: Change in Action Research Arm Test (ARAT) Score — 6.2 units on a scale — p=0.002

Primary: Progression-free Survival (PFS) According to Grade of Rash — 2.16; 6.62; 10.00; 15.28 months — p=0.005

Primary: Distance to Palmar Crease Index Through Small Finger — 6.7; 7.1; 2.3; 2.0 Centimeters — p=0.63

Primary: Overall Response Rate — 11; 2 Participants

Primary: Adverse Events (AEs) - All Participants — 400; 511; 1165; 51 Participants

Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 1; 3; 2; 6 participants

Primary: Percentage of Subjects With Meningococcal C Serum Bactericidal Assay (SBA-MenC) Antibody Titers Above the Cut-off Value — 100; 100 Percentage